阿斯利康(AZN)盘前升1.54% baxdrostat临床试验达成主要和次要研究目标

金吾财讯
Nov 10

金吾财讯 | 阿斯利康(AZN)盘前股价拉升,暂报85.88美元,涨1.54%。

公司表示,其用于治疗难治性高血压患者的实验性药物baxdrostat 在一项三期临床试验中,已达到主要和次要研究目标。

公司称,该药物总体耐受性良好,安全性与早期研究一致。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10